Rab Diagnostics

Rab Diagnostics is addressing a critical unmet need in the rapidly growing ADC therapeutics market: the lack of effective predictive biomarkers for patient selection. The company's core insight is that current selection criteria, based solely on the presence of a cell surface target, are insufficient, as intracellular trafficking proteins like Rab-GTPases are essential for ADC efficacy. Its proprietary platform aims to develop companion diagnostics to improve clinical trial success rates, patient outcomes, and healthcare economics. Founded in 2003 and based in Oslo, the company is a private, likely pre-revenue entity building tools for the entire ADC development lifecycle.

Proprietary RabCANCER platform focused on Rab-GTPases, proteins that regulate endocytosis and intracellular trafficking. The platform uses tools, models, and assays to quantify Rab-GTPase expression as predictive biomarkers for Antibody-Drug Conjugate (ADC) efficacy, aiming to improve patient selection.

The competitive landscape includes academic institutions researching ADC resistance mechanisms and larger diagnostic companies (e.g., Roche, Agilent, Thermo Fisher) with broad capabilities in companion diagnostics. Rab Diagnostics' differentiation lies in its specialized focus on Rab-GTPases and intracellular trafficking as a specific, mechanistic biomarker class for ADCs, rather than just surface target expression.